CD274 and gastric cancer: Currently, FDA has an approved PD-L1-positive expression as a biomarker for third-line treatment of pembrolizumab in gastric cancer (24), and many regions had approved nivolumab for the treatment of unresectable advanced or recurrent GC regardless of PD-L1 expression.